Skip to content
TP

Tonira Pharma Ltd(merged)

530155 BSE
This stock has been delisted or merged and is no longer actively traded.
Price unavailable

In the Dec 2025 quarter, revenue was ₹105 Cr, against ₹89 Cr a year earlier and net profit was ₹16 Cr, against ₹18 Cr a year earlier (compared with Dec 2024). Promoters held 39.01% of Tonira Pharma Ltd(merged) in Dec 2025, unchanged from Sep 2025.

No price data available

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹1,765.8035.034,23,675 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
₹9,625.5087.362,55,527 Cr15.250.32%15.32%18.96%11,682 Cr2,925 Cr
₹4,596.8072.161,74,848 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
₹2,186.00108.001,18,112 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
₹1,181.7026.301,17,875 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
₹1,341.2034.741,11,947 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
₹1,369.8032.821,10,660 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
———————400 Cr45 Cr
Median 8 companies₹1,765.8035.031,18,112 Cr5.070.61%13.79%17.94%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

No Tapetide Score has been computed for this stock yet.

Key Insights

Strengths

1
  • Debtor days have improved from 64.2 to 46.3 days.

Weaknesses

3
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 0.12% over past five years.
  • Company has a low return on equity of 1.45% over last 3 years.

Growth Rate

Revenue Growth
-18% lower than 3Y

change over 1 year

Net Income Growth
-300% lower than 3Y

change over 1 year

Quarterly Results

Particulars Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales
99
134
122
103
106
146
88
98
89
100
96
99
105
Expenses
75
111
97
77
82
125
62
73
62
68
67
77
83
Operating Profit
24
23
25
25
24
21
25
25
27
32
29
22
22
OPM %
24%
17%
21%
25%
23%
14%
29%
25%
30%
32%
30%
22%
21%
Other Income
2
1
3
2
2
7
4
5
4
-40
4
17
8
Interest
2
0
3
1
0
1
1
2
1
2
2
1
1
Depreciation
4
5
5
5
5
6
6
6
6
6
6
6
6
PBT
20
20
21
21
21
21
22
22
24
-16
25
32
22
Tax %
27%
25%
26%
27%
23%
32%
25%
25%
24%
-18%
28%
25%
27%
Net Profit
15
15
15
16
16
14
16
16
18
-13
18
24
16
EPS (₹)
2.23
2.26
2.38
2.29
2.36
1.99
2.28
2.29
2.55
-1.83
2.52
3.3
2.24
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Sales
29.86
36.55
28.61
38.47
36.82
30.04
Expenses
23.59
29.67
29.55
30.18
29.97
26.31
Operating Profit
6.27
6.88
-0.94
8.29
6.85
3.73
OPM %
21%
18.82%
-3.29%
21.55%
18.6%
12.42%
Other Income
0.1
0.2
-3.37
-2.24
0.21
0.28
Interest
1.25
1.81
2.1
3.6
2.88
3.14
Depreciation
2.44
2.57
2.77
2.8
2.84
3.07
PBT
2.68
2.7
-9.18
-0.35
1.34
-2.2
Tax %
35.82%
39.26%
-36.49%
111.43%
23.88%
-5.45%
Net Profit
1.72
1.64
-5.83
-0.74
1.02
-2.08
Div. Payout %
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Equity Capital
7.94
7.94
7.94
7.94
7.94
7.94
Reserves
10.49
12.13
6.3
5.25
6.39
4.31
Borrowings
21.41
19.68
28.91
28.38
31.3
36.74
Other Liabilities
6.1
10.13
8.97
11.47
8.06
6.62
Total Liabilities
45.94
49.88
52.12
53.04
53.69
55.61
Fixed Assets
27.3
27.79
26.21
24.13
24.55
23.41
CWIP
0
0
0.11
0.09
0.54
1.21
Investments
0.12
0.04
0.04
0.04
0.14
0.14
Other Assets
18.52
22.05
25.76
28.78
28.46
30.85
Total Assets
45.94
49.88
52.12
53.04
53.69
55.61
Figures in ₹ Crores

Cash Flow

Particulars Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Operating
-0.57
5.07
-4.71
3.81
7.45
-0.93
Investing
-5.62
-3.27
-1.17
-0.72
-3.82
-2.63
Financing
6.11
-1.72
7.1
-4.12
-1.1
2.7
Net Cash Flow
-0.08
0.08
1.22
-1.03
2.53
-0.86
Free Cash Flow
-6.07
1.8
-5.88
3.09
3.72
-3.56
CFO/OP
-8
74
501
47
115
-20
Figures in ₹ Crores

Ratios

Particulars Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Debtor Days
68.09
40.24
69.15
83.49
62.75
46.29
Inventory Days
316
345
248
256
233
360
Days Payable
120
138
142
180
130
119
Cash Conversion Cycle
264
248
175
160
166
288
Working Capital Days
158
130
173
148
164
257
ROCE %
—
11.36%
-7.6%
14.09%
9.68%
2.07%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Tonira Pharma Ltd(merged) insights

57 extracted metrics + investor summaries across FY06–FY26.

Shareholding Pattern

DIIs0.76%Public56.78%FIIs3.45%Promot.39.01%As ofDec 2025

Documents

Frequently Asked Questions about Tonira Pharma Ltd(merged)

Where is Tonira Pharma Ltd(merged) (530155) listed?
Tonira Pharma Ltd(merged) trades under code 530155 on the BSE.
Which sector does Tonira Pharma Ltd(merged) belong to?
Tonira Pharma Ltd(merged) is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.

Company Information

Website tonira.com
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530155.md for Tonira Pharma Ltd(merged): company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More